TFX

Teleflex is a diversified medical-device maker with attractive underlying product economics — FY2025 gross margin was 56.2% and operating income was positive at $118M (+14.2%) — but the headline -$906M net loss and -$20.25 EPS reflect a large non-cash impairment rather than an operating collapse. The tell is the gap between the deep net loss and the still-positive operating income and gross profit ($1.12B), plus the fact that operating cash flow, though down sharply, remained positive at $96.7M. The write-down most likely relates to goodwill/intangibles from prior or recent M&A.

The genuine concerns are deterioration and leverage. Revenue grew 17.2% to $1.99B — but the multi-year series is distorted by portfolio changes (revenue dropped from $2.81B in FY2021 to $1.71B in FY2023, then rebuilt), and the FY2025 jump came alongside a 63.3% surge in long-term debt to $2.54B, suggesting an acquisition funded the growth. Net income has fallen hard from $356M (2023) to $69.7M (2024) to the FY2025 loss, operating margin compressed to a thin 5.9%, and operating cash flow collapsed 68%. Equity fell 27.0% as the impairment and capital returns eroded the base, lifting liabilities/equity to 1.22x.